<DOC>
	<DOCNO>NCT01927484</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) common disable condition , effective therapy currently exist . Synovitis commonly demonstrate knee OA imaging . Synovial inflammation due release cytokine important cause pain . Methotrexate ( MTX ) help decrease synovitis many inflammatory joint disease , particularly rheumatoid arthritis . The aim present study ass efficacy MTX decrease pain inflammation symptomatic knee OA . Methods : One hundred forty-four patient American College Rheumatology ( ACR ) clinical radiographic criterion primary knee OA knee pain , [ &gt; 4 24-hour average pain severity scale ( 0-10 ) use mean daily rating week precede randomization ] &gt; 14 days/month 3 consecutive month precede enrollment include randomized double-blind placebo-controlled trial . Patients meet eligibility criterion randomize 1:1 ratio receive either 25mg/week oral MTX ( n=72 ) placebo ( n=72 ) together usual therapy provide dosage keep constant 28 week . Pain assess use Visual Analogue pain Scale , ( VAS , 0-100 mm ) . Functional assessment perform use Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) Activities daily live ( ADL ) score . Alterations dosage analgesic/NSAID drug use record . Safety tolerability also assess . Synovitis detect ultrasound imaging .</brief_summary>
	<brief_title>Knee Osteoarthritis AND Methotrexate Use</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>primary knee osteoarthritis persistent pain synovitis rheumatoid arthritis gout pseudogout traumatic arthritis secondary arthritis renal disease liver disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>methotrexate ,</keyword>
	<keyword>osteoarthritis ,</keyword>
	<keyword>pain ,</keyword>
	<keyword>function ,</keyword>
	<keyword>synovitis</keyword>
</DOC>